India, Aug. 11 -- Vor Bio (VOR), a clinical-stage biotechnology company reported its second-quarter 2026 financial results today and provided a corporate update, with investors focusing on continued Phase 3 progress for telitacicept and a cash runway extending into early 2029.
Recent Business & Clinical Updates:
Vor Bio's Phase 3 UPSTREAM MG trial evaluating telitacicept in generalized myasthenia gravis remains on track, with topline results anticipated in 1H 2027.
Enrollment is also ongoing in the global Phase 3 UPSTREAM SjD trial evaluating telitacicept in primary Sjogren's disease.
China's National Medicinal Products Administration approved telitacicept for the treatment of adult patients with Sjogren's disease and IgA nephropathy, m...